Cristina Herrero-Igartua
Research Subjects
Cristina Herrero-Igartua has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Abdessamad Gueddari
Departamento de Química Inorgánica, Orgánica y Bioquímica-Centro de Innovación en Química Avanzada (ORFEO-CINQA), Universidad de Castilla-La Mancha, Ciudad Real, Spain
1 shared publication - Alberto Ocana
Hospital Clinico San Carlos
1 shared publication - Almudena del Campo-Balguerías
Unidad nanoDrug, Centro Regional de Investigaciones Biomédicas, Universidad de Castilla-La Mancha, 02008 Albacete, Spain
1 shared publication - Carlos Alonso-Moreno
Universidad de Castilla-La Mancha
1 shared publication Carmen Martin-Hernandez
1 shared publication- Corina Lorz
Molecular Oncology Unit, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Madrid, Spain
1 shared publication
Latest Publications
- Open Access
Active Liposomal Targeting for Head and Neck Squamous Cell Carcinoma Treatment
Head and neck squamous cell carcinoma (HNSCC) is a major oncological challenge due to its high recurrence rates, biological heterogeneity, and poor long-term survival outcomes. Despite advances in surgery and radiotherapy, chemotherapeutic options are limited. Cisplatin (CDDP) remains the mainstay, while small molecule inhibitors, such as the selective PI3K3CA; inhibitor Alpelisib, are still under clinical evaluation. However, systemic side effects and suboptimal tumor specificity hamper the clinical utility of both standard and novel specific therapies. In this study, we developed passive- and active-targeting liposomes encapsulating Cisplatin (CDDP) and Alpelisib. To achieve active targeting, the anti-epidermal growth factor receptor (EGFR) antibody Cetuximab was conjugated to the liposome surface. All formulations were characterized based on size, morphology, encapsulation efficiency, and drug release profiles. In vitro assays demonstrated that liposomal encapsulation preserved the cytotoxic effects of both CDDP and Alpelisib in HNSCC cell lines, with CDDP showing adequate encapsulation efficiency for in vivo evaluation. In vivo near-infrared fluorescence imaging demonstrated that active-targeting liposomes achieved greater tumor accumulation and a better tumor-to-spleen ratio compared to passive formulations. Tumor growth by CDDP-loaded active-targeting liposomes was comparable to that of the free drug, likely due to the hydrophilic nature and rapid release of CDDP from liposomes in physiological conditions. Importantly, blood chemistry analysis indicated a favorable toxicity profile for the targeted liposomal formulation. These findings highlight the potential of liposome-based targeted strategies to improve therapeutic outcomes in HNSCC and underscore the value of nanotechnology in the development of next-generation oncological therapies.
Open AccessActive Liposomal Targeting for Head and Neck Squamous Cell Carcinoma Treatment
Head and neck squamous cell carcinoma (HNSCC) is a major oncological challenge due to its high recurrence rates, biological heterogeneity, and poor long-term survival outcomes. Despite advances in surgery and radiotherapy, chemotherapeutic options are limited. Cisplatin (CDDP) remains the mainstay, while small molecule inhibitors, such as the selective PI3K3CA; inhibitor Alpelisib, are still under clinical evaluation. However, systemic side effects and suboptimal tumor specificity hamper the clinical utility of both standard and novel specific therapies. In this study, we developed passive- and active-targeting liposomes encapsulating Cisplatin (CDDP) and Alpelisib. To achieve active targeting, the anti-epidermal growth factor receptor (EGFR) antibody Cetuximab was conjugated to the liposome surface. All formulations were characterized based on size, morphology, encapsulation efficiency, and drug release profiles. In vitro assays demonstrated that liposomal encapsulation preserved the cytotoxic effects of both CDDP and Alpelisib in HNSCC cell lines, with CDDP showing adequate encapsulation efficiency for in vivo evaluation. In vivo near-infrared fluorescence imaging demonstrated that active-targeting liposomes achieved greater tumor accumulation and a better tumor-to-spleen ratio compared to passive formulations. Tumor growth by CDDP-loaded active-targeting liposomes was comparable to that of the free drug, likely due to the hydrophilic nature and rapid release of CDDP from liposomes in physiological conditions. Importantly, blood chemistry analysis indicated a favorable toxicity profile for the targeted liposomal formulation. These findings highlight the potential of liposome-based targeted strategies to improve therapeutic outcomes in HNSCC and underscore the value of nanotechnology in the development of next-generation oncological therapies.